Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

Cheng SL, Ho ML, Lai YF, et al. Drug Des Devel Ther. 2020;14:5441–5450.The authors have advised there is an error in the formatting of the paper title on page 5441, the title “Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticaso...

Full description

Bibliographic Details
Main Authors: Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, Huang MS, Lee CH, Lin CH, Hang LW, Liu YC, Yang KY, Wang JH
Format: Article
Language:English
Published: Dove Medical Press 2021-02-01
Series:Drug Design, Development and Therapy
Subjects:
budesonide/formoterol
fluticasone propionate/salmeterol
anti-inflammatory reliever and maintenance
and real-world
Online Access:https://www.dovepress.com/corrigendum-budesonideformoterol-anti-inflammatory-reliever-and-mainte-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/corrigendum-budesonideformoterol-anti-inflammatory-reliever-and-mainte-peer-reviewed-article-DDDT

Similar Items